Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Georgia State Researcher Gets $3.4 Million Grant to Develop Vaccine Technology Against Flu, RSV

Published: Friday, February 01, 2013
Last Updated: Friday, February 01, 2013
Bookmark and Share
Sang-Moo Kang received grant to bolster research that will lead to better flu vaccines and vaccines against respiratory syncytial virus (RSV), a disease for which there is no vaccine.

The grant from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases will aid Kang’s research in developing a virus-like particle, or VLP, vaccine technology.

VLPs mimic viruses, but are non-infectious, which allows for safer vaccines, especially for young children, elderly people and patients whose immune systems are compromised. VLPs trigger the immune system to respond, leading to immunity in the same way that regular vaccines made with whole viruses act.

“VLPs are a result of new technology using recombinant genetic engineering,” Kang said. “VLP technology can manipulate pathogens in a safe way so that we can design a vaccine mimicking the shape and structure of a virus.

“A VLP is an empty particle without the genetic information of a pathogen, thus highlighting its safety.”

The potential of this research could lead to not only better vaccines for influenza, which is potentially deadly in some patients and which has led to deaths during this year’s flu season, but also RSV.

RSV is a respiratory virus that infects the lungs and breathing passages. Most healthy people can recover from RSV infection in one to two weeks, but infections can be severe in young children, infants and older adults.

According to the Centers for Disease Control and Prevention, about 75,000 to 125,000 hospitalizations related to RSV occur among children under one year old, and RSV infection results in about 1.5 million outpatient medical visits among children under the age of five.

Kang’s lab will test VLP technology and ways to deliver the vaccines without long needles, such as nasal delivery, microneedles and oral vaccination.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos